ViaCyte to Present at ARM's Third Annual Regen Med Investor Day
Press release from the issuing company
Wednesday, March 18th, 2015
ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Paul Laikind, President and CEO, at the third annual Regen Med Investor Day co-hosted by the Alliance for Regenerative Medicine and top financial firm Piper Jaffray.
Details of the presentation are as follows:
|
Session: |
Company Presentations |
|
Date/Time: |
Wednesday, March 25th at 10:35 a.m. EDT |
|
Location: |
Main Bar Room, Metropolitan Club, New York, N.Y. |
Dr. Laikind will review recent progress with the company's VC-01™ product candidate for the treatment of type 1 diabetes, which recently entered the clinical phase of development. A Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type 1 Diabetes, was launched in September 2014, and the first implant was announced in October 2014. The study is ongoing, with evaluation of safety and efficacy expected next year.
For more information, please visit the event's website at www.arminvestorday.com.
